(Q43265083)

17 November 2017

title

Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits (English)

1 reference

17 November 2017

Ting Fan Leung

1

1 reference

17 November 2017

Yvonne Chu

2

1 reference

17 November 2017

Vincent Lee

3

1 reference

17 November 2017

Frankie W T Cheng

4

1 reference

17 November 2017

Wing Kwan Leung

5

1 reference

17 November 2017

Matthew M K Shing

6

1 reference

17 November 2017

Chi Kong Li

7

1 reference

17 November 2017

publication date

1 January 2009

1 reference

17 November 2017

1 reference

17 November 2017

volume

33

1 reference

17 November 2017

issue

5

1 reference

17 November 2017

page(s)

361-369

1 reference

High prevalence of low bone mass in thalassaemia major.

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F03630260903210377

Longitudinal monitoring of bone mineral density in thalassemic patients. Genetic structure and osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03630260903210377

Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03630260903210377

Determinants of axial and peripheral bone mass in Chinese adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03630260903210377

Bisphosphonates in the treatment of thalassemia-associated osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03630260903210377

Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03630260903210377

Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (DEXA).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03630260903210377

Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03630260903210377

Bisphosphonates in the treatment of thalassemia-induced osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03630260903210377

Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03630260903210377

Prevalence of fractures among the Thalassemia syndromes in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03630260903210377

Bone disease in thalassemia: a frequent and still unresolved problem

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03630260903210377

10.3109/03630260903210377

21 January 2018

Identifiers

DOI

1 reference

17 November 2017

1 reference